$RNTX News
Last published 1w ago
- 1w agoRNTXRein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireAUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis
- 2mo agoRNTXRein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 CongressGlobeNewswireAUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis
- 2mo agoRNTXRein Therapeutics to Present at Upcoming September Investor ConferencesGlobeNewswireAUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis
- 2mo agoRNTXRein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary FibrosisGlobeNewswireDesignation reflects serious unmet need in idiopathic pulmonary fibrosis (IPF), where approved therapies slow but do not halt disease progressionActively enrolling patients in the RENEW Phase 2 trial evaluating LTI-03
- 2mo agoRNTXRein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireSurpassed 25% enrollment milestone in the Global Phase 2 RENEW trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF); on track to report interim data in the second half of 2026Successfully completed
- 3mo agoRNTXRein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature CommunicationsGlobeNewswireData support ongoing Phase 2 "RENEW" trialFirst-in-human clinical study produced measurable reductions in multiple markers of lung scarring and inflammation in IPF patientsStudy confirms LTI-03 was safe and
- 3mo agoRNTXRein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five CountriesGlobeNewswireGlobal Expansion Complete as Germany Joins Ongoing Study of Inhaled LTI-03 in Idiopathic Pulmonary FibrosisCompany on track to report initial topline data in 2H 2026 AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) --
- 5mo agoRNTXRein Therapeutics Expands Phase 2 RENEW Trial into United KingdomGlobeNewswire16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)First patient randomized in the United KingdomClinical trial sites now actively enrolling in the United States, Australia, and the
- 5mo agoRNTXRein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment OptionGlobeNewswireTotal gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May
- 6mo agoRNTXRein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common StockGlobeNewswireAUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class
- 6mo agoRNTXRein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary FibrosisGlobeNewswirePatient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near termEnrollment initiated in March 2026, with
- 8mo agoRNTXRein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary FibrosisGlobeNewswireAUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet
- 9mo agoRNTXRein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary FibrosisGlobeNewswireAUSTIN, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical
- 1y agoRNTXRein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPFGlobeNewswireAUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical
- 1y agoRNTXRein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisGlobeNewswireFDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not
- 1y agoRNTXRein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisGlobeNewswireEMA approval covers study sites in Germany and Poland as part of the Company's global Phase 2 RENEW trialTrial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair
- 1y agoRNTXRein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary FibrosisGlobeNewswireAUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet
- 1y agoRNTXRein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary FibrosisGlobeNewswireAUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs
- 1y agoRNTXRein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025GlobeNewswireAUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical
- 1y agoENTARNTXWVEXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery CollaborationPR NewswireXtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery,...
- 1y agoRNTXRein Therapeutics Enters into Agreements for up to $21 Million in Flexible FinancingGlobeNewswireAUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical
- 1y agoRNTXRein Therapeutics Announces Adjournment of Annual Meeting of StockholdersPR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medications to address...
- 1y agoRNTXIQVRein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPFPR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International ConferencePR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatePR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPFPR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPFPR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics to Present at The Citizens Life Sciences Conference 2025PR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International ConferencePR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory DiseasesPR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-FPR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXRein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatePR NewswireRein Therapeutics, Inc. (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant...
- 1y agoRNTXALRNAileron Therapeutics Announces Rebranding to Rein TherapeuticsPR NewswireRein Therapeutics ("Rein") (NASDAQ: RNTX), formerly known as Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company...